Shots:
In the next installment of Dealmaker 2023, we bring an informative report on the Top M&A based on the Deal Value
The report revolves around Pfizer, which signed 16 collaborations comprising acquisitions, contract services, development & commercialization, license, R&D, and product purchases that have summed to a total of $63.23B
Propelled by the invaluable…
Shots:
As the year began, PharmaShots was busy analyzing the deals throughout 2023 to prepare a special report, viz. JP Morgan 2024 Special: Deal Maker of the Year 2023 (Part 01)
The report features Roche, that signed 26 collaborations comprising acquisitions, contract services, development & commercialization, license, R&D, and product purchases
Propelled by the invaluable…
2023, remained a busy year for PharmaShots. To keep our readers up to date on the developments in the healthcare sector, PharmaShots worked steadfastly to deliver real-time and real-world updates. Here’s a synopsis of our key reports and most-read news of the year.
Top 20 Radiopharma Companies Based on Market Cap
Shots:
Integrating scintigraphy with…

